Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Potential pharmacologic treatments for cystinuria and for calcium stones associated with hyperuricosuria.

Goldfarb DS.

Clin J Am Soc Nephrol. 2011 Aug;6(8):2093-7. doi: 10.2215/CJN.00320111. Epub 2011 Jul 14. Review.

2.

Treatment of calcium nephrolithiasis in the patient with hyperuricosuria.

Arowojolu O, Goldfarb DS.

J Nephrol. 2014 Dec;27(6):601-5. doi: 10.1007/s40620-014-0084-x. Epub 2014 Apr 1. Review.

3.

Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group.

Prezioso D, Strazzullo P, Lotti T, Bianchi G, Borghi L, Caione P, Carini M, Caudarella R, Ferraro M, Gambaro G, Gelosa M, Guttilla A, Illiano E, Martino M, Meschi T, Messa P, Miano R, Napodano G, Nouvenne A, Rendina D, Rocco F, Rosa M, Sanseverino R, Salerno A, Spatafora S, Tasca A, Ticinesi A, Travaglini F, Trinchieri A, Vespasiani G, Zattoni F; CLU Working Group.

Arch Ital Urol Androl. 2015 Jul 7;87(2):105-20. doi: 10.4081/aiua.2015.2.105. Review. Erratum in: Arch Ital Urol Androl. 2016 Mar;88(1):76. Ferraro, Manuel [added].

4.

Cystine growth inhibition through molecular mimicry: a new paradigm for the prevention of crystal diseases.

Lee MH, Sahota A, Ward MD, Goldfarb DS.

Curr Rheumatol Rep. 2015 May;17(5):33. doi: 10.1007/s11926-015-0510-7. Review.

5.

[Clinical value of crystalluria study].

Daudon M, Jungers P, Lacour B.

Ann Biol Clin (Paris). 2004 Jul-Aug;62(4):379-93. Review. French.

6.

[Hyperuricosuria and urolithiasis].

Koide T.

Nihon Rinsho. 1996 Dec;54(12):3273-6. Review. Japanese.

PMID:
8976104
7.

Prevention and treatment of kidney stones.

[No authors listed]

J Urol. 1989 Mar;141(3 Pt 2):804-8. Review. No abstract available.

PMID:
2645439
8.

Consensus conference. Prevention and treatment of kidney stones.

[No authors listed]

JAMA. 1988 Aug 19;260(7):977-81. Review. No abstract available.

PMID:
3294456
9.

Formation of renal stones may be prevented by restoring normal urinary composition.

Pak CY.

Proc Eur Dial Transplant Assoc. 1983;20:371-85. Review. No abstract available.

PMID:
6361751
10.

How should patients with cystine stone disease be evaluated and treated in the twenty-first century?

Andreassen KH, Pedersen KV, Osther SS, Jung HU, Lildal SK, Osther PJ.

Urolithiasis. 2016 Feb;44(1):65-76. doi: 10.1007/s00240-015-0841-x. Epub 2015 Nov 27. Review.

PMID:
26614112
11.

Update on cystinuria.

Sumorok N, Goldfarb DS.

Curr Opin Nephrol Hypertens. 2013 Jul;22(4):427-31. doi: 10.1097/MNH.0b013e3283621c5d. Review.

12.

Optimum nutrition for kidney stone disease.

Heilberg IP, Goldfarb DS.

Adv Chronic Kidney Dis. 2013 Mar;20(2):165-74. doi: 10.1053/j.ackd.2012.12.001. Review.

PMID:
23439376
13.

Cystinuria: definition, epidemiology and clinical aspects.

Trinchieri A, Dormia G, Montanari E, Zanetti G.

Arch Ital Urol Androl. 2004 Sep;76(3):129-34. Review.

PMID:
15568305
14.

[Gout: an overview of available urate lowering therapies].

Richette P.

Ann Pharm Fr. 2012 May;70(3):133-8. doi: 10.1016/j.pharma.2012.02.003. Epub 2012 Apr 27. Review. French.

PMID:
22655581
15.

Nutritional aspects of stone disease.

Hess B.

Endocrinol Metab Clin North Am. 2002 Dec;31(4):1017-30, ix-x. Review.

PMID:
12474643
16.

[From gene to disease; SLC3A1, SLC7A9 and cystinuria].

Breuning MH, Hamdy NA.

Ned Tijdschr Geneeskd. 2003 Feb 8;147(6):245-7. Review. Dutch.

PMID:
12621979
17.

Cystinuria.

Mattoo A, Goldfarb DS.

Semin Nephrol. 2008 Mar;28(2):181-91. doi: 10.1016/j.semnephrol.2008.01.011. Review.

PMID:
18359399
18.

Etiology and treatment of urolithiasis.

Pak CY.

Am J Kidney Dis. 1991 Dec;18(6):624-37. Review.

PMID:
1962646
19.

Stones from bowel disease.

Worcester EM.

Endocrinol Metab Clin North Am. 2002 Dec;31(4):979-99. Review.

PMID:
12474641
20.

The hyperuricosuric calcium oxalate stone former.

Sarig S.

Miner Electrolyte Metab. 1987;13(4):251-6. Review.

PMID:
3306317

Supplemental Content

Support Center